Stay updated on Sacituzumab vs Chemo in HR+/HER2- Metastatic Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Sacituzumab vs Chemo in HR+/HER2- Metastatic Breast Cancer Clinical Trial page.

Latest updates to the Sacituzumab vs Chemo in HR+/HER2- Metastatic Breast Cancer Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedNIH funding reference for 2018 was added to the funding information. A new publication citation by Sathe et al. on Sacituzumab Govitecan pharmacokinetics was added to the Publications/IPD section, and the revision tag was updated from v3.6.5 to v3.6.6.SummaryDifference0.1%

- Check41 days agoChange DetectedThe page shows Revision: v3.6.5 replacing v3.6.4. This indicates a minor update to the page’s revision, likely affecting internal documents or UI rather than the study content.SummaryDifference0.0%

- Check56 days agoChange DetectedThe page now displays a new revision tag Revision: v3.6.4, replacing the previous v3.6.3. This indicates an internal version update that does not alter the study content or user-facing data.SummaryDifference0.0%

- Check77 days agoChange DetectedThe page's revision label was updated from v3.6.2 to v3.6.3, signaling a minor documentation update.SummaryDifference0.0%

- Check84 days agoChange DetectedThe page's revision line changed from Revision: v3.6.0 to Revision: v3.6.2. This update indicates a newer build of the Study Details page.SummaryDifference0.0%

- Check98 days agoChange DetectedThe page adds a recruitment status line 'No longer looking for participants' and introduces new help and join sections (How to Read a Study Record, Common Questions, How to Join a Study), with a formatting change from 'Intervention / Treatment' to 'Intervention/Treatment'. The study record version reference updated from v3.5.5 to v3.6.0.SummaryDifference0.2%

Stay in the know with updates to Sacituzumab vs Chemo in HR+/HER2- Metastatic Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Sacituzumab vs Chemo in HR+/HER2- Metastatic Breast Cancer Clinical Trial page.